[go: up one dir, main page]

MX2019008331A - Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. - Google Patents

Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.

Info

Publication number
MX2019008331A
MX2019008331A MX2019008331A MX2019008331A MX2019008331A MX 2019008331 A MX2019008331 A MX 2019008331A MX 2019008331 A MX2019008331 A MX 2019008331A MX 2019008331 A MX2019008331 A MX 2019008331A MX 2019008331 A MX2019008331 A MX 2019008331A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
pharmaceutical use
janus kinase
novel amino
imidazopyridine derivatives
Prior art date
Application number
MX2019008331A
Other languages
English (en)
Inventor
Larsen Mogens
Kyhn Rasmussen Lars
Marianne Duus Tine
Larsen Jens
Ritzen Andreas
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of MX2019008331A publication Critical patent/MX2019008331A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un compuesto de acuerdo con la fórmula (I) Ver formula. o sales, hidratos o solvatos farmacéuticamente aceptables de estos; donde R, es alquiloC1, R2 es alquilo C1, R3 es alquilo C2, R4 es hidrógeno, Rs es hidrógeno. La invención se refiere además a los compuestos para uso en terapia, a composiciones farmacéuticas que comprenden los compuestos, a los compuestos para uso en el tratamiento de enfermedades autoinmunitarias y a Intermediarios para la preparación de los compuestos.
MX2019008331A 2017-01-11 2018-01-10 Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. MX2019008331A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17151020 2017-01-11
PCT/EP2018/050548 WO2018130563A1 (en) 2017-01-11 2018-01-10 Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof

Publications (1)

Publication Number Publication Date
MX2019008331A true MX2019008331A (es) 2020-01-14

Family

ID=57777557

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008331A MX2019008331A (es) 2017-01-11 2018-01-10 Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.

Country Status (26)

Country Link
US (1) US10703751B2 (es)
EP (1) EP3568396B1 (es)
JP (1) JP7009504B2 (es)
KR (1) KR102548543B1 (es)
CN (1) CN110167938B (es)
AU (1) AU2018208516B2 (es)
BR (1) BR112019014191A2 (es)
CA (1) CA3045567A1 (es)
CY (1) CY1123864T1 (es)
DK (1) DK3568396T3 (es)
ES (1) ES2846741T3 (es)
HR (1) HRP20210095T1 (es)
HU (1) HUE052720T2 (es)
IL (1) IL267829B (es)
LT (1) LT3568396T (es)
MX (1) MX2019008331A (es)
MY (1) MY195576A (es)
PL (1) PL3568396T3 (es)
PT (1) PT3568396T (es)
RS (1) RS61317B1 (es)
RU (1) RU2019125177A (es)
SI (1) SI3568396T1 (es)
TW (1) TWI760419B (es)
UA (1) UA123972C2 (es)
WO (1) WO2018130563A1 (es)
ZA (1) ZA201904190B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220885T1 (hr) 2016-12-16 2022-12-09 Janssen Pharmaceutica Nv Spojevi imidazo[4,5-d]pirolo[2,3-b]piridina kao inhibitori janus kinaze
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
US20210269447A1 (en) * 2018-07-06 2021-09-02 Leo Pharma A/S Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
WO2021040502A1 (ko) * 2019-08-30 2021-03-04 주식회사 티에스디라이프사이언스 이미다조피리딘 유도체 및 이를 유효성분으로 함유하는 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240488B1 (en) * 2008-02-06 2016-11-02 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
AR079984A1 (es) * 2010-01-12 2012-03-07 Hoffmann La Roche Compuestos heterociclicos triciclicos, composiciones y su uso en el tratamiento de enfermedades mediadas por la inhibicion de jak1
US9115127B2 (en) * 2010-08-05 2015-08-25 Amgen Inc. Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2527344A1 (en) * 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
UY34616A (es) * 2012-02-10 2013-09-30 Galapagos Nv Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
TWI646099B (zh) 2012-11-01 2019-01-01 英塞特控股公司 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
CA2891655A1 (en) * 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
CN104098563A (zh) * 2013-04-02 2014-10-15 山东亨利医药科技有限责任公司 Jnk抑制剂化合物
MA39987A (fr) * 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
RS62695B1 (sr) 2016-10-03 2022-01-31 Highlightll Pharmaceutical Hainan Co Ltd Novi jak1 selektivni inhibitori i njihove upotrebe
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز

Also Published As

Publication number Publication date
AU2018208516B2 (en) 2021-07-08
WO2018130563A1 (en) 2018-07-19
CA3045567A1 (en) 2018-07-19
EP3568396A1 (en) 2019-11-20
BR112019014191A2 (pt) 2020-02-11
US10703751B2 (en) 2020-07-07
TW201829407A (zh) 2018-08-16
UA123972C2 (uk) 2021-06-30
EP3568396B1 (en) 2020-11-11
JP7009504B2 (ja) 2022-01-25
SI3568396T1 (sl) 2021-04-30
AU2018208516A1 (en) 2019-07-11
DK3568396T3 (da) 2021-01-18
CN110167938B (zh) 2024-06-14
KR20190103231A (ko) 2019-09-04
JP2020504186A (ja) 2020-02-06
PL3568396T3 (pl) 2021-05-31
US20190367512A1 (en) 2019-12-05
HUE052720T2 (hu) 2021-05-28
ES2846741T3 (es) 2021-07-29
CN110167938A (zh) 2019-08-23
TWI760419B (zh) 2022-04-11
ZA201904190B (en) 2020-10-28
KR102548543B1 (ko) 2023-06-29
RS61317B1 (sr) 2021-02-26
IL267829B (en) 2022-02-01
MY195576A (en) 2023-02-02
CY1123864T1 (el) 2022-05-27
RU2019125177A (ru) 2021-02-15
LT3568396T (lt) 2021-02-10
HRP20210095T1 (hr) 2021-03-05
IL267829A (en) 2019-09-26
RU2019125177A3 (es) 2021-05-11
PT3568396T (pt) 2021-02-09

Similar Documents

Publication Publication Date Title
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
PH12020551821A1 (en) Novel compounds
MX2021013472A (es) Moduladores de thr-? y metodos de uso de estos.
PH12016501440A1 (en) Novel heterocyclic compounds
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2017010735A (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
MX2015008971A (es) Derivados de pirimidina pirido- o pirrolo-fusionados como inhibidores de autotaxina para tratar dolor.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
HK1138262A1 (en) Novel phosphodiesterase inhibitors
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
PH12019550083A1 (en) Inhibitors of bruton's tyrosine kinase
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
PH12022553420A1 (en) Amidopyrimidone derivatives
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate